Akebia Therapeutics reports strong Q2 2025 earnings, driven by Vafseo’s 55% sales growth. Explore plans for expanded patient access & trial updates.

Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial evaluating CTIM-76 at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting.

The National Agency for Food and Drug Administration and Control (NAFDAC) has assured Nigerians that genetically modified ...

Procter & Gamble (PG) reported fourth quarter results, warning that it will take a $1 billion hit from tariffs in full-year ...

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., ...

Variety’s 2025 class of New Leaders is an antidote to that type of thinking, proving that a time of contraction and ...

Saudi Arabia’s leading purpose-driven healthcare and wellbeing Company, today reported its financial results for the second ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Company Announcement, European Regulatory News, GlobeNewswire, Pharmaceuticals | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L ...

The community of Cardigan celebrates the successful purchase and transformation of the Tabernacl Chapel into a vibrant ...